Gilead wins US patent trial over HIV prevention drugs

A federal jury ruled in favor of Gilead on Tuesday in a long-running patent battle over the use of its HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP). While Truvada and Descovy were initially approved for the treatment of HIV in 2004 and 2016, respectively, they each won approvals…

...

Click to view original post